Video

Dr. Mok on the Importance of Global Collaboration to Improve Cancer Care

Tony S. K. Mok, MD, BMSc, FRCPC, FASCO, discusses the importance of improving cancer research through collaboration as a Giant of Cancer Care®.

Tony S. K. Mok, MD, BMSc, FRCPC, FASCO, chairman of the Department of Clinical Oncology and Li Shu Fan Professor of Clinical Oncology at The Chinese University of Hong Kong, discusses the importance of improving cancer research through collaboration as a Giant of Cancer Care®.

It was an honor to become a Giant of Cancer Care®, according to Mok. Having been trained as a medical professional in Canada and having moved back to Hong Kong, China over the course of 25 years, Mok was able to establish a link between Asia, the United States, and Europe. This kind of link allows doctors from around the world to work together and collaborate to ultimately improve the quality of cancer research in the Asian-Pacific region and hopefully benefit cancer care on a global scale, Mok says.

This award is a recognition of this effort to connect researchers, says Mok. However, Mok explains that this is not an effort that is being made by him alone; rather, this a global effort is being made to link Asia with the rest of the world in the fight to improve care for patients with cancer.

Related Videos
Alec Watson, MD
Balazs Halmos, MD
Balazs Halmos, MD
Suresh Senan, MRCP, FRCR, PhD, full professor, treatment and quality of life, full professor, cancer biology and immunology, full professor, radiation oncology, professor, clinical experimental radiotherapy, Amsterdam University Medical Centers
Alison Schram, MD
Mary B. Beasley, MD, discusses molecular testing challenges in non–small cell lung cancer and pancreatic cancer.
Mary B. Beasley, MD, discusses the multidisciplinary management of NRG1 fusion–positive non–small cell lung cancer and pancreatic cancer.
Mary B. Beasley, MD, discusses the role of pathologists in molecular testing in non–small cell lung cancer and pancreatic cancer.
Mary B. Beasley, MD, discusses the role of RNA and other testing considerations for detecting NRG1 and other fusions in solid tumors.
Mary B. Beasley, MD, discusses the prevalence of NRG1 fusions in non–small cell lung cancer and pancreatic cancer.